Stocks Health care PLSE
NASDAQ · Health carePulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. brought in $1.5M of revenue over the twelve months to September 30, 2026, up 1,637.2% from a year earlier. It posted a net loss of $83.7M. In fiscal 2025 capital spending exceeded operating cash flow by $54.4M. At September 30, 2026 it held $36.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Pulse Biosciences, Inc.
- Net worth
- Pulse Biosciences, Inc. has a market value (market cap) of $4.1B at the latest share price, and shareholders' equity of $183.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $350K, with a net loss of $72.8M. Over the 12 months to September 30, 2026: revenue $1.5M, net loss $83.7M.
- Cash flow
- In fiscal 2025 operations used $54.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Pulse Biosciences, Inc.'s next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Pulse Biosciences, Inc. does
Pulse Biosciences, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PLSE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $350K | -$72.8M | -$1.08 | -$54.4M |
| 2024 | $0 | -$53.6M | -$0.92 | -$36.5M |
| 2023 | $0 | -$42.2M | -$0.85 | -$33.2M |
| 2022 | $700K | -$58.5M | -$1.72 | -$47.4M |
| 2021 | $1.4M | -$63.7M | -$2.28 | -$54.5M |
| 2020 | $0 | -$49.9M | -$2.14 | -$35.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PLSE ranks in Health care
Latest SEC filings
What Pulse Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Other event 8-K
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 359% to $395K versus the same quarter last year; diluted EPS -$0.32 versus -$0.29.
- November 5, 2026
- October 14, 2026Other event 8-K
- October 7, 2026Other event 8-K
- September 15, 2026
- September 15, 2026Other event 8-K
- August 6, 2026
- August 6, 2026
- August 6, 2026
Insider trades
What the people running Pulse Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $199.9K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Teplitsky Liane RaeChief Operating Officer | Bought | 1,001 | $50K |
| August 31, 2026 | Teplitsky Liane RaeChief Operating Officer | Bought | 1,024 | $50K |
| August 28, 2026 | Teplitsky Liane RaeChief Operating Officer | Bought | 1,034 | $50K |
| August 26, 2026 | Teplitsky Liane RaeChief Operating Officer | Bought | 1,036 | $50K |
| May 11, 2026 | Duggan Robert WDirector, 10% owner | Bought | 660,233 | $13M |
| May 11, 2026 | Duggan Robert WDirector, 10% owner | Bought | 660,233 | $13M |
| May 11, 2026 | Laviolette Paul AChief Executive Officer, Director | Bought | 15,000 | $295.4K |
| May 11, 2026 | Laviolette Paul AChief Executive Officer, Director | Bought | 15,000 | $295.4K |
Who owns PLSE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Robert W. Duggan13D, may seek influence with 2 related filers | 71.9% | May 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 106 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 1,466,702 | +126,924 |
| Bank of America Corp | 1,446,611 | +580,550 |
| Vanguard Capital Management LLC | 788,640 | -27,212 |
| Portolan Capital Management, LLC | 753,333 | +19,961 |
| Balyasny Asset Management L.P. | 718,103 | +452,939 |
| Citadel Advisors LLC | 626,514 | +484,364 |
| Geode Capital Management, LLC | 536,276 | +44,330 |
| State Street Corp | 529,624 | +72,697 |
| Massachusetts Financial Services Co | 462,734 | -165 |
| UBS Group AG | 275,669 | +241,715 |
| Griffin Asset Management, Inc. | 227,285 | +2,108 |
| Vanguard Portfolio Management LLC | 179,497 | +14,296 |
| Northern Trust Corp | 173,590 | -13,682 |
| Charles Schwab Investment Management Inc | 151,991 | +4,223 |
| Vanguard Fiduciary Trust Co | 131,253 | +647 |
| Point72 Asset Management, L.P. | 106,457 | new |
| Norges Bank | 105,647 | new |
| Nuveen, LLC | 101,683 | +56,248 |
| Panoramic Capital, LLC | 98,054 | +40,000 |
| D. E. Shaw & Co., Inc. | 81,818 | +68,092 |
Insiders
4 insiders reported holding 48,433,286 shares in total, about $2.82B at the last price.
| Holder | Shares |
|---|---|
| Duggan Robert WDirector, 10% owner | 48,370,047 |
| Danahy Kevin PatrickChief Commercial Officer | 43,298 |
| Laviolette Paul AChief Executive Officer, Director | 15,846 |
| Teplitsky Liane RaeChief Operating Officer | 4,095 |
Questions about PLSE
What does Pulse Biosciences, Inc. do?
Pulse Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as PLSE. Its shares trade on NASDAQ under the ticker PLSE.
What is Pulse Biosciences, Inc.'s net worth?
Pulse Biosciences, Inc. has a market value (market cap) of $4.1B at the latest share price, and shareholders' equity of $183.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pulse Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $83.7M on revenue of $1.5M.
How much revenue does Pulse Biosciences, Inc. make?
Over the twelve months to September 30, 2026 Pulse Biosciences, Inc. reported revenue of $1.5M. That is 1,637.2% more than a year earlier.
When did Pulse Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the other event from November 6, 2026.
When is Pulse Biosciences, Inc.'s next earnings report?
Pulse Biosciences, Inc.'s next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PLSE with
Follow PLSE
Get an email when Pulse Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pulse Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.